The United States government and the Wellcome Trust have joined forces to build Carb-X, an ambitious, risk-taking funding partnership dedicated to antimicrobial resistance. Lindsay McKenzie reports.
The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) was launched in July 2016, funded initially with $250 million from the US government. The Wellcome Trust also pitched in for an undisclosed, but in its own words “very significant” contribution.
CARB-X has run two calls putting a total of $70m on offer to researchers anywhere in the world. The most recent closed on 31 October and a third is expected to be launched in 2017.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.